Home
Scholarly Works
Dual antiangiogenic therapy using lenalidomide and...
Conference

Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Authors

Adesunloye B; Huang X; Ning YM; Madan RA; Gulley JL; Beatson M; Kluetz PG; Adelberg DE; Arlen PM; Parnes HL

Volume

30

Publisher

AMER SOC CLINICAL ONCOLOGY

Publication Date

May 20, 2012

Name of conference

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Conference place

Chicago, IL

Conference start date

June 1, 2012

Conference end date

June 6, 2012

Conference proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

15

ISSN

0732-183X

Labels

Fields of Research (FoR)

Contact the Experts team